Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …

Background In individuals with migraine, attacks may increase in frequency, severity, or
both. Preventing migraine progression has emerged as a treatment goal in headache …

Background and objectives The identification of predictors of response to antiCGRP mAbs
could favor tailored therapies and personalized treatment plans. This study is aimed at …

Background Fremanezumab has demonstrated to be effective, safe, and tolerated in the
prevention of episodic or chronic migraine (CM) in randomized, placebo-controlled trials …

Background Criteria, including clinical features and effective outcomes, for access and
persistence of novel but costly treatments may vary between countries, thus affecting the …

Background In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in
chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their …

Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as
antagonists of the CGRP receptor or ligand. They can be divided into monoclonal antibodies …

Background and purpose A rapid response to preventive therapy is of pivotal importance in
severely disabled patients with chronic migraine (CM) and diverse preventive treatment …

Background Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its
receptor (anti-CGRP (-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) …

Background Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP)
pathway are effective and safe on migraine prevention. However, some drug agencies …